Clinical Trials Logo

Clinical Trial Summary

This study is to compare 2-year Disease Free Survival Rate (DFSR) in post radical operation IIIA Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) 19 or 21 exon mutation treated Erlotinib vs NP chemotherapy as adjuvant therapy.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01683175
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact
Status Active, not recruiting
Phase Phase 2
Start date August 2012
Completion date October 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05557552 - Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly and/or Frail Stage III Non-small-cell Lung Cancer N/A
Active, not recruiting NCT04765709 - Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC Phase 2
Not yet recruiting NCT06031597 - Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy Phase 3
Recruiting NCT04728724 - Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer Phase 2
Not yet recruiting NCT05451173 - Combining ICI With SBRT or HypoFrx-RT for ES NSCLC Phase 1/Phase 2
Completed NCT06015815 - The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT
Completed NCT03728556 - A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer Phase 3
Recruiting NCT04586465 - Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC Phase 2
Not yet recruiting NCT05548504 - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC Phase 2
Completed NCT02434081 - NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma Phase 2
Not yet recruiting NCT02946216 - ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC N/A
Completed NCT03550482 - Oncoxin® and Quality of Life in Cancer Patients Phase 4
Recruiting NCT05398094 - Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy Phase 2
Completed NCT02418234 - T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure N/A
Recruiting NCT05338619 - A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy Phase 2
Not yet recruiting NCT05414630 - A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer Phase 2
Withdrawn NCT04941365 - Quantifying Systemic Immunosuppression to Personalize Cancer Therapy N/A
Active, not recruiting NCT04699721 - Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC Phase 1
Recruiting NCT04878952 - Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer N/A
Recruiting NCT04716946 - Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy Phase 2